PCCA博客 保持当前PCCA新闻和事件,市场趋势,和一切雪上加霜!//www.browskids.com/Blog 药剂师联系议员支持复合 //www.browskids.com/Blog/pharmacists-connecting-with-lawmakers-in-support-of-compounding?PostId=202 药房立法和监管 2021年结婚,07年7月13:05:30 GMT <风格type = " text / css " >。PCCABlogPost .PCCABlogBullets {list-style-type:广场!重要;padding-left: 40 px !重要;}.PCCABlogPost .sub-bullet {list-style-type:圆!重要;padding-left: 40 px !重要;}< /风格> < div class = " PCCABlogPost " > < p > < em >艾米柄,PCCA政府关系总监< / em > < / p > < p > 2021年6月,超过70个人报名参加了一年一度的PCCA行动(行动,承诺和时间)的立法会议。事件的目标是让复利药剂师与他们在华盛顿的立法者建立关系,华盛顿特区,所以,政策制定者更了解药房复合。更明智的人更有可能做出以病人为中心的决策。会议是国会以来虚拟办公室尚未对公众开放的大型集团会议。< / p > < p >议员由选民了解复利——包括PCCA成员——往往是最支持的病人获得复合药物。 Our hope is that these champions will engage the Food and Drug Administration (FDA) and others about barriers that could restrict or eliminate a pharmacist’s ability to lawfully compound a medication, despite a patient-specific prescription from a health care provider. What follows is a brief summary of the conference highlights.

PCCA’s 2021 ACT Legislative Conference by the Numbers

  • 2 pharmacists serving in Congress addressed the conference:
    • Representatives Diana Harshbarger, R-TN, and Buddy Carter, R-GA, spoke about the need to educate lawmakers on issues impacting pharmacy compounding and patients
  • 5 additional lawmakers delivered remarks:
    • Representatives Henry Cuellar, D-TX; Diana DeGette, D-CO; Morgan Griffith, R-VA; Dr. John Joyce, R-PA; and Markwayne Mullin, R-OK, also addressed ACT participants
  • 110 congressional appointments were held between pharmacists and lawmakers
    • These meetings were supported by PCCA team members, along with support from our trade associations the Alliance for Pharmacy Compounding and the National Community Pharmacists Association

What Pharmacists Asked of Their Legislators

  • Preserve patients’ access to compounded hormones
  • Sign a Congressional letter to the FDA — led by Reps. Henry Cuellar, D-TX, and Neal Dunn, MD, R-FL — asking the FDA to delay enforcement of the memorandum of understanding (MOU) to allow more time for states to review the policy
  • Cosponsor legislation that would allow access to compounds needed for urgent medical situations and during drug shortages (H.R. 3662)
  • Ask the FDA to withdraw their animal compounding guidance and work with compounding pharmacy stakeholders on a revised proposal
  • Call for the FDA to allow all ingredients with United States Pharmacopeia and National Formulary monographs — including dietary supplement monographs — to be lawfully compounded
  • Send a letter to the Centers for Medicare and Medicaid Services asking for Medicare patients to have access to compounded medications by reimbursing them for compounds made from active pharmaceutical ingredients

We encourage compounding pharmacists, prescribers and patients to stay informed on the issues that could affect the ability to prescribe, compound medication or take a compounded medication. If PCCA members have questions or requests for additional information, they can contact our Public Affairs team at publicaffairs@pccarx.com.

Also on The PCCA Blog: What the FDA’s Final MOU Means for Your Practice

Amy Shank, PCCA’s Director of Government Relations, previously served as Vice President of Capitol Hill Consulting Group, where she advised pharmacy, pharmaceutical and university clients on federal legislative priorities. Amy also has over 10 years of experience in the United States Senate. She was the Director of Oversight and Investigations for the Senate Health, Education, Labor and Pensions Committee. She was also a senior policy advisor to the Senate HELP Committee. Amy was a senior analyst for the Chairman of the Senate Budget Committee, former Senator Don Nickles, R-OK, and began her legislative career in his Republican Whip office as a policy advisor.

202年